TEL-AVIV, Israel, Jan. 09, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma
Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty
biopharmaceutical company primarily focused on the development and commercialization
of late clinical-stage, proprietary, orally-administered, small molecule drugs
for gastrointestinal and inflammatory diseases and cancer, today announced the
presentation of an abstract relating to YELIVA®, the Company’s
proprietary, first-in-class, orally-administered sphingosine kinase-2 (SK2)
selective inhibitor, at the 2017 Cholangiocarcinoma Foundation Annual
Conference, on February 2, 2017, in Salt Lake City, UT.
The abstract, entitled ‘Targeting Sphingosine Kinase-2 for the Treatment
of Cholangiocarcinoma (CCA)’1, was authored by scientists from
the Mayo Clinic, Apogee Biotechnology Corp. (Apogee), the Medical University of
South Carolina (MUSC) and RedHill. It will be presented by one of its authors,
Dr. Lewis R. Roberts, M.B., Ch.B., Ph.D, a gastroenterologist and hepatologist
at Mayo Clinic and the External Co-Chair of The Cancer Genome Atlas (TCGA)
Cholangiocarcinoma Project of the National Cancer Institute (NCI).
SOURCE: RedHill Biopharma Ltd.
No comments:
Post a Comment